YB18
YB18 is an antimicrobial peptide targeting Gram-negative bacteria. YB18 exhibits low hemolytic activity, acceptable cytocompatibility at antibacterial-related concentrations, and membrane-associated bactericidal behavior. YB18 disrupts bacterial membrane permeability and membrane potential. In an in vivo wound model infected with Escherichia coli, topical administration of YB18 reduces bacterial load. YB18 can be used for research on Gram-negative bacterial infections.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C51H92N18O8
- Masse moléculaire:1085.39
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
In Vitro
YB18 inhibits the growth of P. aeruginosa ATCC 27853, E. coli MG1655, K. pneumoniae ATCC 700603, and A. baumannii ATCC 19606, with MIC values of 16, 8, 8, and 16 μM, and MBC values of 16, 32, 128, and 64 μM, respectively[1].
YB18 (8-64 μM; 18 h) inhibits the growth of clinically isolated Gram-negative strains, with MIC values ranging from 8 to 64 μM against *E. coli*, *K. pneumoniae*, *P. aeruginosa* and *A. baumannii* strains[1].
YB18 (2-256 μM; 1 h) exhibits low hemolytic activity against rat red blood cells, with a hemolysis rate of less than 1% even at a concentration as high as 256 μM[1].
YB18 (2-64 μM; 24 h) exhibits favorable cytocompatibility with RAW 264.7, L929, and NIH 3T3 cells at antibacterial relevant concentrations of 8-16 μM, whereas reduced cell viability is observed at higher concentrations[1].
YB18 (0-120 min) shows limited stability in 25% rat serum, retaining only 5% of its initial concentration after 120 min of incubation[1].
YB18 (6-15 mM) forms a viscoelastic hydrogel at a concentration of 12 mM in 0.8× PBS, which exhibits stable gel-like mechanical properties, partial self-recovery behavior, and a dense fibrous self-assembled microstructure[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW 264.7, L929, and NIH 3T3 cell lines
-
Concentration:2-64 μM
-
Incubation Time:24 h
-
Result:Maintained acceptable cell viability at antibacterial-relevant concentrations (8-16 μM) across all three cell lines, with viability decreasing in a concentration-dependent manner at higher concentrations (32-64 μM).
In Vivo
YB18 (12 mM hydrogel in 0.8× PBS; topical; once daily for 11 consecutive days) reduces E. coli load in wounds of infected mice, accelerates wound healing and improves tissue repair, with antibacterial efficacy comparable to that of Polymyxin B (HY-149179)[1].
YB18 (12 mM hydrogel in 0.8× PBS; topical administration; once daily for 5 consecutive days) shows preliminary local tolerability in male and female BALB/c mice, with no skin abnormalities or histological injuries observed[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (male)[1]
-
Dosage:10 mg/kg; 20 mg/kg
-
Administration:topical; every 24 h; 2 doses total
-
Result:Achieved an approximately 2-3 log10 CFU/g reduction in wound bacterial burden relative to the saline control.
Showed antibacterial efficacy comparable to that of polymyxin B under the tested conditions.
-
Animal Model:BALB/c[1]
-
Dosage:12 mM YB18 hydrogel in 0.8× PBS
-
Administration:topical; once daily; 11 days total
-
Result:Reduced viable bacterial counts in wound tissues to levels comparable to polymyxin B and significantly lower than the PBS control on day 3.
Showed faster wound area reduction than the infected PBS group from day 0 to day 11, with more rapid wound contraction and closure observed via photographic and image analysis.
Revealed improved tissue repair relative to the infected PBS group via endpoint H&E staining.
-
Animal Model:BALB/c (male, female)[1]
-
Dosage:12 mM YB18 hydrogel in 0.8× PBS
-
Administration:topical; once daily; 5 days total
-
Result:Showed no obvious macroscopic skin abnormalities in male or female mice during the 5-day treatment period.
Did not reveal overt treatment-related epidermal or dermal damage in either sex relative to PBS-treated controls via endpoint H&E staining.
Chemical Information
-
Masse moléculaire 1085.39
-
Formule C51H92N18O8
-
SMILES
O=C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCNC(N)=N)N
-
Sequence
Arg-Phe-Arg-Leu-Ile-Leu-Arg-Leu-NH2
-
Sequence Shortening
RFRLILRL-NH2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
YB18 Related Classifications
HY-P11940 Related Classifications
Powered by Bioz